Publication Date
1-1-2022
Journal
Gastro Hep Advances
DOI
10.1016/j.gastha.2022.05.005
PMID
36117550
PMCID
PMC9481069
PubMedCentral® Posted Date
5-14-2022
PubMedCentral® Full Text Version
Post-Print
Published Open-Access
yes
Keywords
Enteroendocrine Cells, Diabetes Treatment, Cell Cycle, Parietal Cells, Transcription Factor
Abstract
BACKGROUND AND AIMS: Stomach cells can be converted to insulin-producing cells by Neurog3, MafA, and Pdxl over-expression. Enteroendocrine cells can be similarly made to produce insulin by the deletion of FOXO1. Characteristics and functional properties of FOXO1-expressing stomach cells are not known.
METHODS: Using mice bearing a FOXO1-GFP knock-in allele and primary cell cultures, we examined the identity of FOXO1-expressing stomach cells and analyzed their features through loss-of-function studies with red-to-green fluorescent reporters.
RESULTS: FOXO1 localizes to a subset of Neurog3 and parietal cells. FOXO1 deletion ex vivo or in vivo using Neurog3-cre or Atp4b-cre increased numbers of parietal cells, generated insulin- and C-peptide-immunoreactive cells, and raised Neurog3 messenger RNA. Gene expression and ChIP- seq experiments identified the cell cycle regulator cyclin E1 (CCNE1) as a FOXO1 target.
CONCLUSION: FOXO1 is expressed in a subset of stomach cells. Its ablation increases parietal cells and yields insulin-immunoreactive cells, consistent with a role in lineage determination.
Included in
Digestive System Diseases Commons, Gastroenterology Commons, Medical Sciences Commons, Oncology Commons
Comments
Associated Data